Burden of Chemo-Induced Myelosuppression Among Patients With ES-SCLC…

Lowell Hart

National Platinum Chemo Shortages: Impact on Lung Cancer Treatment a…

Jerome Goldschmidt

New Drugs for Small Cell Lung Cancer

Stanford Medicine

M. Das

Radiation Combined With IO for the Treatment of SCLC

Weill Cornell Medicine Oncology & Hematology

A. Saxena

The Importance of Staying on Therapy for SCLC to Achieve Optimal Ben…

Misty Shields

ASCO® 2023 Insights: "SWOG S1929 Phase II Randomized Study - Mainten…

Insights from 2023 ASCO® Annual Meeting

N. Abdel Karim

ASCO® 2023 Insights: "Randomized Phase 3 DeLLphi-304 Study - Tarlata…

Insights from 2023 ASCO® Annual Meeting

L. Paz-Ares

UNC Lineberger Comprehensive Cancer Center Updates in RT for SCLC

UNC Lineberger Comprehensive Cancer Center

A. Weiner

ASCO® 2023 Insights: "Final Survival Data From a Randomized Phase 2 …

Insights from 2023 ASCO® Annual Meeting

B. Henning Grønberg

ASCO® 2023 Insights: "CASPIAN Study Phase 3 Updates: The Prognostic …

Insights from 2023 ASCO® Annual Meeting

A. Ganti

Leveraging SCLC Subtypes and Other Biomarkers

Icahn School of Medicine at Mount Sinai

F. Hirsch

ADCs in SCLC

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

A. Chiang

Trilaciclib and the Economic Value of Multilineage Myeloprotection F…

Ivo Abraham

Current Treatment Landscape in SCLC

Northwell Health

N. Seetharamu

Recent Advances in SCLC

OncoAlert

J. Naidoo

Consolidation Strategies in SCLC: IO and Radiation

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

N. Abdel Karim

Emergence of Immunotherapy in Small Cell Lung Cancer

Antoinette Wozniak